Tech Digest

Japan’s Economic Sun May Rise Again Thanks to Anti-Aging Medicine

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

September 11, 2017

Dear Reader,

Note: Today’s article was written prior to Hurricane Irma hitting Patrick’s home state of Florida. He is currently out of contact.

The Japanese people are well-educated and industrious. In the 1960s, Japan’s economic growth rate was often over 10%, rising to an astounding 13%. By the 1980s, pundits and economists were telling us that the US should be copying Japanese economic policies. I knew people who studied Japanese because they were convinced that it would be the international language of business.

In 1989, Sony paid nearly $7 billion in current dollars for Columbia Pictures. Shortly afterward, Mitsubishi Estate Company of Tokyo bought Rockefeller Center. That includes Radio City Music Hall and 19 high-rise office buildings in the heart of America’s most prestigious section of real estate.

Japan appeared to be an economic juggernaut. At the time, the total price of Tokyo’s real estate was valued on paper higher than the entire land mass of the United States.

Behind the scenes, however, something was changing. About 18 years before Mitsubishi bought the heart of Manhattan, Japanese birth rates went into freefall. Few noticed.

Most economists ignored birth rates as a factor in economic growth. This is probably because peacetime populations had always grown. Since we’d never seen anything else, few wondered about the alternative. Moreover, it takes at least 18 years for changes in birth rates to hit the work force.

When the supply of new workers stagnated, Japan’s economic growth rate fell by more than half. It wasn’t attributed to birth rates, however, and most economists assumed the downturn was temporary. Despite a shrinking population of future taxpayers, spending did not go down. Debt increased.


In the early 1990s, Mitsubishi was hurting due to the collapse in Japanese economic growth. Then, rents dipped in Manhattan. Mitsubishi filed for bankruptcy protection and walked away from Rockefeller Center.

More importantly, Japan entered its “Lost Decade.” That lost decade stretched into decades. Pundits who had held Japanese policies up as the model for economic growth came up with new theories.

Only today are economists beginning to recognize the connection between birth and economic growth rates. It’s not the sole factor, but it should have been obvious. GDP is, after all, worker productivity multiplied by the number of workers. The connection is mathematical, not theoretical.

The connection between fertility and economic strength goes further than total population, however. Economists have recently begun to look at the impact of the increase in average worker age on economic vigor and growth.

Younger workers are willing to do the harder jobs and put in more hours than older workers. Without the vigor of youth, the economy changes. Today, Japan is struggling to fill even its most basic blue-collar positions. With much more time to recover from failures, younger white-collar workers are also bigger risk takers—a prerequisite for innovation.

To make up for missing revenues caused by a shrinking worker base, Japan borrowed staggering amounts of money to fund services for its rapidly aging population. Debt, however, reduces economic growth rates. Poor economic conditions further reduce birth rates.

Today, Japan pursues two conflicting goals. One is to get more women into the work force to pay down the debt. The other is to make it easier for women to have babies. Even women who want larger families are often forced to work to make ends meet.

One solution is to lower taxes to give families more options. That can’t happen, however, without reducing government spending significantly. We know how hard it is to cut government budgets.  

The other solution is to keep older Japanese healthier and working longer. This would reduce the burden on Japanese taxpayers and give families more freedom to have additional children.

The Japanese know this and have instituted a radical regulatory reform called “conditional approval.” This system allows biotechs with new anti-aging therapies to sell products that have passed safety trials. This means that the entire Japanese public can participate in self-funding efficacy trials. In that way, we get evidence about the effectiveness of those therapies. 

When President Trump was choosing his new FDA chief, he considered several candidates who favor conditional approval for the US. The enormous industry that profits from the current regulatory model fought back with all its resources. And Trump backed down.

At some point, the US, Europe, and the rest of the developed world will adopt the Japanese regulatory model. There is no other option.

In the last months, I’ve had discussions with several companies developing extremely promising anti-aging therapies. All of them are actively exploring partnerships with Japanese companies that can navigate that country’s regulatory waters. Several have made important but unheralded deals.

I am convinced that effective anti-aging and regenerative medicine is the biggest financial opportunity of the 21st or any other century. Most of these therapies could be provided via health tourism.

Japanese clinics could easily serve wealthy Americans and Europeans who want to turn back the clock of biological aging. Japan, out of necessity, has taken the first steps toward cornering that market. Studying Japanese may turn out to be a smart business decision after all.

Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics


Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest

Your privacy is very important to us. Please review our Privacy Policy.


« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This

We welcome your comments. Please comply with our Community Rules.


There are no comments at this time.

Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact


The Mauldin Economics website, Thoughts from the Frontline, The Weekly Profit, The 10th Man, Connecting the Dots, Transformational Technology Digest, Over My Shoulder, Yield Shark, Transformational Technology Alert, Rational Bear, Street Freak, ETF 20/20, In the Money, and Mauldin Economics VIP are published by Mauldin Economics, LLC Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2018 Mauldin Economics